Lazard Asset Management Form 8.3 - Xeris Pharmaceuticals, Inc (2596N)
September 28 2021 - 8:21AM
UK Regulatory
TIDM0A8E
RNS Number : 2596N
Lazard Asset Management
28 September 2021
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing Lazard Asset Management
(Note 1) Ltd
Company dealt in XERIS PHARMACEUTICALS
INC
========================
Class of relevant security Ordinary shares
to which the dealings
being disclosed relate
(Note 2)
========================
Date of dealing 27 September 2021
========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========= ====== ============ =====
2,636,288
(1) Relevant securities 147,719 0.222% 3.964%
================= ===================
(2) Derivatives (other
than options)
================= ===================
(3) Options and agreements
to purchase/sell
================= ===================
2,636,288
Total 147,719 0.222% 3.964%
================= ===================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
========= ====== ============ =====
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(Note 5)
Sell 2500 USD 2.67
Sell 18970 USD 2.5618
====================================== ====================
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
CFD Short Sell 8326 USD 2.5612
CFD Short Sell 4869 USD 2.6703
===================== ================== ===========
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to
the
voting rights of any relevant securities under any option
referred to on this form or relating to
the voting rights or future acquisition or
disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none,
this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 28 September 2021
Contact name Harrison Leney
=================
Telephone number 020 7448 2335
=================
If a connected EFM, name
of offeree/offeror with
which connected
=================
If a connected EFM, state
nature of connection (Note
10)
=================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEMZGZLFRLGMZM
(END) Dow Jones Newswires
September 28, 2021 09:21 ET (13:21 GMT)
Xeris Biopharma (LSE:0A8E)
Historical Stock Chart
From Oct 2024 to Nov 2024
Xeris Biopharma (LSE:0A8E)
Historical Stock Chart
From Nov 2023 to Nov 2024
